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Abstract 
Microbubbles are widely used as contrast agents to improve the diagnostic capability of 
conventional, highly speckled, low-contrast ultrasound imaging. However, while microbubbles can 
be used for molecular imaging, these agents are limited to the vascular space due to their large size 
(> 1 μm). Smaller microbubbles are desired but their ultrasound visualization is limited due to 
lower echogenicity or higher resonant frequencies. Here we present nanometer scale, phase 
changing, blinking nanocapsules (BLInCs), which can be repeatedly optically triggered to provide 
transient contrast and enable background-free ultrasound imaging. In response to irradiation by 
near-infrared laser pulses, the BLInCs undergo cycles of rapid vaporization followed by 
recondensation into their native liquid state at body temperature. High frame rate ultrasound 
imaging measures the dynamic echogenicity changes associated with these controllable, periodic 
phase transitions. Using a newly developed image processing algorithm, the blinking particles are 
distinguished from tissue, providing a background-free image of the BLInCs while the underlying 
B-mode ultrasound image is used as an anatomical reference of the tissue. We demonstrate the 
function of BLInCs and the associated imaging technique in a tissue-mimicking phantom and in vivo 
for the identification of the sentinel lymph node. Our studies indicate that BLInCs may become a 
powerful tool to identify biological targets using a conventional ultrasound imaging system. 
Key words: Microbubbles, ultrasound imaging 
Introduction 
Ultrasound contrast agents provide acoustic 
backscatter due to a mismatch in impedance between 
the gas core of microbubbles and the surrounding, 
water-based soft tissue. Contrast is also enhanced due 
to compressibility of their gaseous cores compared to 
surrounding tissues, resulting in mechanical 
oscillations of the bubbles. Signal enhancement from 
microbubbles was first demonstrated using 
echocardiography in 1968.(1) Since then, a variety of 
microbubbles and molecular targeting strategies have 
been explored to assist in the identification of early 
disease states.(2) However, despite the echogenicity of 
microbubbles against a soft tissue background, the 
local image contrast is hindered by the abundant 
sub-wavelength acoustic scatterers in most biological 
tissues.(3–5) To combat this issue, several functional 
contrast agents and nonlinear imaging techniques 
have been implemented. For example, harmonic and 
pulse inversion imaging utilize the nonlinear 
oscillatory behavior of microbubbles in response to 
ultrasound irradiation, which can help distinguish 
them from the background tissue.(6,7) However, the 
harmonic response of tissues limits the specificity of 
this technique, and tissue motion degrades the 
detection of microbubbles.(8–10) Additionally, 
microbubbles are confined to the vascular space due 
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to their large size,(11) and their circulation time is 
limited to a few minutes as gas diffuses from the 
bubble core.(12) 
A new generation of nano-sized triggerable 
particles, referred to as phase-change nanodroplets, is 
emerging to address these limitations. These stable 
liquid droplets vaporize in response to either a pulsed 
laser or ultrasound, providing contrast enhancement 
activated by an external trigger.(13–17) When droplets 
are vaporized using a pulsed laser, they 
simultaneously emit a strong photoacoustic signal, 
facilitating multimodal imaging.(13,14,18) Their small 
size enables access to extravascular targets, and their 
liquid core results in a more stable particle (hours) 
(Supplementary Information, Fig. S1) than 
conventional microbubbles.(12) Several groups have 
previously developed perfluorocarbon (PFC) droplet 
nanoemulsions for imaging and therapeutic 
applications. Work by Sheeran et al. reports well 
characterized, acoustically activatable PFC emulsions 
for ultrasound and pulse inversion imaging 
applications.(19) Rapoport et al. have encapsulated 
therapeutics for a highly stable particle capable of 
simultaneous imaging and ultrasound-triggered drug 
delivery.(20) Other groups have encapsulated 
photoabsorbers for optical activation. Wilson et al. 
first reported laser-induced droplet vaporization for 
simultaneous ultrasound and photoacoustic 
imaging.(14) Strohm et al. reported similar results 
using droplets with incorporated quantum dots 
activated by 1064 nm light for improved 
photoacoustic contrast.(15) Akers et al. used a high 
boiling point PFC with encapsulated dye for a stable 
particle capable of extended photoacoustic 
contrast.(21) Larson-Smith et al. report the 
well-studied synthesis of a gold-nanoparticle 
stabilized nanoemulsion.(22) To enable extended 
imaging, several groups have used higher boiling 
point PFC particles capable of repeated vaporization. 
Rapoport et al. demonstrated repeated ultrasonic 
activation of a highly stable particle.(20) Asami et al. 
incorporated a dye into a high boiling point PFC 
droplet and vaporized it repeatedly for prolonged 
photoacoustic contrast.(23) Arnal et al. report the 
synthesis of a gold particle shelled PFC emulsion and 
a high contrast, real-time ultrasound/photoacoustic 
imaging technique using synchronized laser 
pulses.(24,25) Each of these strategies utilizes a 
combination of particle properties, laser energy, 
optical triggering, and ultrasound imaging techniques 
to obtain high contrast biomedical image information. 
This work aims to improve image contrast, depth 
sensitivity, and particle stability to enhance diagnostic 
information. 
 
Here we report stable, dynamic contrast agents 
called BLInCs, which respond to optical irradiation 
for a background-free, ultrasound-based image of the 
particles. The BLInCs consist of a liquid 
perfluorohexane (PFH) core, which has a bulk boiling 
point of 56°C, resulting in a stable liquid droplet at 
physiological temperatures (Fig. 1a). The submicron 
BLInCs are encapsulated by a fluorosurfactant 
polymer shell, which lowers the interfacial surface 
tension.(26) The high curvature of the interface 
increases the Laplace pressure between the PFH core 
and the surrounding water, further stabilizing the 
particles in a nano-sized state.(27) The BLInCs 
incorporate a near-infrared absorbing dye and can be 
activated by irradiating them with a pulsed laser. In 
response to irradiation (Fig. 1a), the dye catalyzes 
rapid (< 1-2 µs) droplet vaporization (Fig. 1b-c), 
behavior observed in other PFC particles.(13–15) The 
resulting transient gaseous microbubbles (Fig. 1c), 
which persist for up to several milliseconds, reflect 
ultrasound waves before recondensing back into their 
stable, weakly scattering nanodroplet form (Fig. 1d). 
This two-part phase change (liquid  gas  liquid) 
“blinking” process can be measured (Fig. 1e) using 
any clinical ultrasound imaging system capable of 
high speed imaging techniques, such as ultrafast or 
parallel beam imaging. The BLInCs can be activated 
repeatedly by a series of laser pulses, inducing brief 
moments of high echogenicity during their gaseous 
phase. When imaged, this behavior differentiates 
them from tissue, and the data can be processed to 
form a background-free image of the BLInCs. When 
combined with their size, the controllable dynamics of 
the BLInCs may enable a wide array of high contrast 
molecular ultrasound imaging and therapeutic 
applications. 
Materials and Methods 
Synthesis of BLInCs 
First, 1 mg of Epolight 3072 dye (Epolin, Inc.) 
was added to 300 µL of PFH (FluoroMed, L.P.) and 
dissolved by sonication at 180 W for 30 s in a VWR 
benchtop ultrasonic cleaner. Then 1 mL of 1% v/v 
aqueous Zonyl FSO fluorosurfactant (Sigma) and 1.7 
mL of deionized water were added to the PFH. The 
mixture was emulsified by vortexing for 10s and 
sonicated for 2 minutes at 180 W in a VWR benchtop 
ultrasonic cleaner. The nanodroplets were washed of 
excess dye and fluorosurfactant by centrifuging at 
1000 rcf for 5 minutes and replacing the supernatant 
with deionized water. The BLInCs were diluted and 
then manually counted under a light microscope to 
obtain an estimate of their concentration after 
synthesis. 
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Figure 1. (a) The BLInCs comprise a liquid PFH core with an encapsulated near-infrared dye stabilized by a surfactant shell. The particles are activated using a pulsed 
laser. In their native state (b), the liquid BLInCs are weakly scattering and largely undetectable by ultrasound. Upon activation (c), the BLInCs undergo a rapid liquid-gas 
phase change, rendering them temporarily hyperechoic. The BLInCs recondense back to their native liquid state (d), able to be activated again. (e) Pulse-echo 
ultrasound image intensity from the periodic, laser-induced two-part phase changes. 
 
Characterization of dye’s optical absorption 
and BLInCs’ size  
A small amount of the dye was dissolved in 
chloroform and its extinction spectrum was measured 
with a UV-3600 UV-Vis spectrometer (Shimadzu). A 
Zetasizer Nano ZS system (Malvern Instruments Ltd.) 
was used to measure the diameters of a 1% v/v 
solution of as-prepared BLInCs, at 15 measurements 
per run. An intensity-weighted distribution is 
reported. 
Optical verification of BLInC phase change 
behavior 
A DMI 3000B inverted light microscope 
microscope (Leica Microsystems) was used to observe 
a 0.01% v/v solution of perfluoropentane droplets. A 
50 mJ/cm2 pulsed laser irradiated the sample to form 
stable bubbles, and another image was collected 
several minutes later. The temperature of the bubbles 
was reduced to induce bubble recondensation. 
Approximately 1 minute later, a final image of the 
liquid droplets was collected. 
Synthesis of Phantoms Containing BLInCs 
Two types of phantoms were constructed: one 
with a uniform distribution of BLInCs, and another 
consisting of a BLInC-labeled cylindrical inclusion 
within a BLInC-free background. To construct the 
phantoms, 64 mL of water was mixed with 21 mL of 
40% acrylamide (Ambion) and 850 μL of 438 mM 
aqueous ammonium persulfate (Sigma-Aldrich). The 
solution was stirred in a Büchner flask with a rubber 
stopper to seal the top, and a tube connected to the 
side attached to a vacuum. The solution was sonicated 
under vacuum for 5 minutes to remove dissolved gas, 
and then the vacuum was removed to stir in 
additional components, using one of two 
formulations listed below. 
Phantom with uniform incorporation of BLInCs: 
A solution of as-prepared, 180 nm diameter BLInCs 
was added to the solution so that the entire phantom 
contained 0.1% or 0.001% v/v of the as-prepared 
BLInCs solution. Next, 106 μL of 
tetramethylethylene-diamine (TEMED) (Sigma) was 
added. The entire solution was quickly poured into a 
rectangular mold and allowed to polymerize for 10 
minutes. 
Phantom containing BLInC-labeled cylindrical 
inclusion within BLInC-free background: 5 μm 
Min-U-Sil silica particles (U.S. Silica) were added at 
0.2% w/w, and graphite particles (Dixon) were added 
at 0.01% w/w to mimic the optical absorption (2-3 
cm-1) and acoustic scattering (1-2 dB MHz-1) of 
biological tissue.(28,29) Next, 106 μL of TEMED was 
added. The solution was quickly poured into a 
rectangular mold, where a 1.2 mm diameter sealed 
glass tube was positioned to create a cylindrical void 
in the phantom. After polymerizing, another solution 
was prepared which included 0.1% v/v of 180 nm 
diameter BLInCs and excluded graphite particles. The 
solution was poured into the cylindrical cavity, and 
allowed to polymerize. The final concentration of 
BLInCs in the inclusion was approximately 108/mL. 
 Theranostics 2016, Vol. 6, Issue 11 
 
http://www.thno.org 
1869 
Imaging of BLInCs in Phantom 
Each phantom was placed under a 40 MHz 
imaging probe connected to a Vevo 2100 ultrasound 
imaging system. The imaging probe and phantom 
surface were coupled using clear ultrasound gel. 
Optical fiber bundles were used to deliver 1064 nm 
pulsed laser light from a Phocus Mobile laser system 
(Opotek Inc.) to the phantom. Ultrasound B-mode 
data was collected while the phantom was irradiated 
with 5 ns laser pulses at a rate of 10 Hz. Image data 
from 1000 frames over a period of ~3.5 seconds were 
collected. For the phantoms with uniformly 
distributed BLInCs, the laser fluence was varied from 
5 to 20 mJ/cm2, with a frame rate of either 380 or 650 
frames/second. The ultrasound window was 3.08 mm 
wide, 15 mm deep with a 1 mm offset, and a 10 mm 
focal depth. For the phantom with a cylindrical 
inclusion, the laser fluence was 50 mJ/cm2, the frame 
rate was 580 frames/second, and the ultrasound 
window was 4.08 mm wide, 15 mm deep with a 1 mm 
offset, with a focal depth of 13 mm. For the phantom 
with the inclusion, the estimated fluence at the depth 
of the inclusion was 6-12 mJ cm-2. 
To visualize a three-dimensional volume, 21 
image slices were collected 160 μm apart for a total 
elevational distance of 3.2 mm. At each location, a set 
of 1000 frames was acquired. The 2D or 3D IQ B-mode 
data was obtained for processing, and linear image 
intensity was calculated by (I2 + Q2)1/2. The image data 
were further analyzed by custom-designed MATLAB 
functions and routines. Three-dimensional images 
were created using Amira (FEI Visualization Sciences 
Group). 
Formation of Background-Free Ultrasound 
Image of BLInCs 
To identify the location of the BLInCs in an 
otherwise low contrast ultrasound image, a set of 
B-mode ultrasound images was analyzed. This 
technique utilizes the transmission of multiple US 
waves, followed by subtraction of subsequent 
received signals, similar to that used in pulse 
inversion imaging.(6) Positive values of the 
differential intensity denote increases in echogenicity 
from vaporization, and negative spikes correspond to 
recondensation of the bubbles into droplets. Pixels not 
containing BLInCs, even though equally irradiated by 
the laser light, did not exhibit these changes. To form 
a map of the particles, two separate images were first 
constructed. The first image was formed by 
calculating a mean of the absolute value of the 
difference values at frames corresponding to 
activation by the laser. To make the second image, a 
temporal autocorrelation of the absolute value of the 
differential ultrasound intensity was calculated. Next, 
the ratio of the two greatest values of the 
autocorrelation was calculated, using a delay 
corresponding to the 10 Hz laser repetition rate. The 
value of this ratio was then converted to image 
intensity. The final image was created by pixel-wise 
multiplication of the two previously formed images. 
This map of BLInCs was then overlaid onto a B-mode 
image. A more detailed description of the formation 
of a background-free image can be found in the 
Supplementary Information. Contrast and contrast-to- 
noise ratio were calculated using previously reported 
methods (18). 
Ultrasound Imaging of Lymph Node  
All animal studies were performed under 
protocols approved by the Institutional Animal Care 
and Use Committee at The University of Texas at 
Austin.  
A previously developed mouse model of lymph 
node drainage was used (30–32) in which a nude 
Nu/Nu mouse (Charles River Laboratories) was 
injected submucosally in the tongue with BLInCs. 
Prior to injection, the mouse was anesthetized with a 
combination of isoflurane (1.5%) and O2 (2 L/min). A 
30-gauge needle was used to inject 40 µL of 
as-prepared BLInCs over the course of approximately 
10 s. The BLInCs were allowed to drain for 30 minutes 
at which point ultrasound imaging was performed on 
the cervical lymph nodes located in the mouse’s neck. 
Clear ultrasound gel was used for acoustic coupling 
between the transducer to the mouse. Ultrasound 
images were acquired with a Vevo 2100 
(VisualSonics) using a 40-MHz linear array transducer 
(MS-550) at a rate of 618 frames/second. Light with a 
wavelength of 1064 nm was generated by a Vibrant 
Nd:YAG laser (Opotek) operating at 10 Hz and 
coupled to a custom fiber bundle. The optical fluence 
of approximately 50 mJ/cm2 irradiating the mouse 
was well below the safety limit of 100 mJ/cm2 for 
human skin exposure established by the American 
National Standards Institute.(33) The ultrasound 
window was 4.08 mm wide, 15 mm deep with a 4 mm 
offset, and a focal depth of 9 mm. Immediately 
following the imaging, the mouse was euthanized via 
an overdose of isoflurane (5%) and cervical 
dislocation. 
Results 
Photographs of the dye dissolved in chloroform, 
a solution of blank droplets, and a solution of BLInCs 
indicate the presence of the dye in the droplet solution 
(Fig. 2a). The extinction spectrum of the dye exhibits 
peak absorption in the near-infrared range (Fig. 2b). A 
histogram of droplet diameters indicates their 
submicron size (Fig. 2c). 
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Figure 2. (a) Photographs of the (left) encapsulated dye, (middle) blank perfluorocarbon droplets, and (right) BLInCs. (b) Optical extinction spectrum of the 
encapsulated near-infrared absorbing dye. (c) Distribution of particle sizes.  
 
Figure 3. Light microscope images of BLInCs (a) before activation, (b) after activation, and (c) after recondensation into a liquid state. Scale bar = 20 μm. 
 
Microscope images of the droplets before (Fig. 
3a) and after (Fig. 3b) irradiation confirm an increase 
in particle diameter after vaporization, which is 
concurrent with other studies indicating a 5x increase 
in diameter.(15,34) Following recondensation, the 
droplets reverted to their original size (Fig. 3c). 
The changes in echogenicity of a phantom (0.1% 
v/v BLInCs) exposed to various laser fluences 
demonstrate the importance of selecting proper laser 
energy. Perfluorohexane has a boiling point of 56° C, 
and the Laplace pressure of nano-sized droplets 
further stabilizes the BLInCs in a liquid state at 
physiological temperatures. When the BLInCs were 
irradiated below their vaporization threshold, they 
failed to exhibit any measurable changes in 
ultrasound echogenicity (Fig. 4a, black and Fig. 4b), 
and the background-free imaging technique was 
ineffective. When irradiated with sufficient energy, 
the BLInCs underwent rapid liquid-gas vaporization 
phase changes, followed immediately by gas-liquid 
condensation, resulting in brief increases in 
ultrasound signal from acoustic reflections by the 
bubbles (Fig. 4a, blue). However, identifying these 
momentary changes from the ultrasound images is 
difficult (Fig. 4c). When irradiated with much higher 
energy, the BLInCs underwent irreversible liquid-gas 
vaporization and exhibited a stable increase in 
ultrasound signal (Fig. 4a, red). While this provided 
lasting increase in echogenicity (Fig. 4d), a lack of 
‘blinking’ behavior renders the image processing 
technique ineffective to suppress the background 
signal and provide a high contrast map of the BLInCs.  
The two-part phase change of BLInCs was 
demonstrated using ultrasound imaging (650 
frames/second) of a phantom with uniformly 
distributed BLInCs at a concentration of 0.001% v/v. 
The initially weakly scattering BLInCs (Fig. 5a) 
temporarily appear as bubbles (Fig. 5b) upon 
activation before recondensing back into their liquid 
state (Fig. 5c). While easy to see in a non-scattering 
phantom, the normal acoustic scattering of biological 
tissues disguises the phase change, especially at low 
BLInC concentrations. 
Images of a phantom with a cylindrical inclusion 
show the contrast enhancement by the BLInCs in an 
environment that mimics the optical absorption and 
acoustic scattering of biological tissues.(35) The 
contrast of the BLInCs against an acoustic scattering 
background is not high using conventional 
ultrasound imaging techniques (contrast = 0.76, 
contrast-to-noise ratio = -0.73 dB) (Fig. 6a). However, 
a measurement of the ultrasound signal over time 
shows that pixels within the inclusion undergo 
reversible phase changes, while pixels in the 
background are unaffected by laser pulses (Fig. 6b). 
Difference images enhance the signal from the 
blinking particles while suppressing the constant 
background (Fig. 6c), because the derivative of an 
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unchanging signal is close to zero (Fig. 6d). While it 
was most common for the ultrasound signal to exhibit 
changes in the positive direction (BLInCs underwent a 
liquid-gas-liquid phase change), some pixels 
exhibited negative changes. This may have resulted 
from moving bubbles, or a reverse phase changed 
induced by positive pressure of the vaporized BLInCs 
nearby. For this reason, an absolute value of the 
derivative signal was used to capture a phase change 
in either direction. Further enhancement of the signal 
(Fig. 6e) was achieved using the autocorrelation of the 
derivative (Fig. 6f). This resulted in a large value at 
delay = 0 for pixels both inside and outside of the 
inclusion, but also yielded high values for delays at 
intervals equal to the pulse repetition frequency of the 
laser. By applying the image processing described in 
the Materials and Methods section, a high contrast 
map of the particles was constructed and overlaid 
onto an ultrasound background for anatomical 
reference. The image quality was greatly improved, 
and the location of the BLInCs was identified more 
easily (contrast = 2.8, contrast-to-noise ratio = 25 dB) 
(Fig. 6g). 
 
 
Figure 4. (a) Linear ultrasound signal from an image pixel of a phantom containing BLInCs irradiated with 5 mJ/cm2 (black), 8 mJ/cm2 (blue), and 20 mJ/cm2 (red). 
Ultrasound images before and after irradiation at (b) 5, (c) 8, and (d) 20 mJ/cm2. Scale bars = 1 mm. 
 
Figure 5. Ultrasound images of BLInCs (a) before activation, (b) after activation, and (c) after recondensation into a liquid state. Scale bar = 1 mm. 
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Figure 6. (a) Ultrasound image of a cross-section of a phantom with inclusion of BLInCs. (b) Linear ultrasound signal as a function of time for two pixels, one within 
the inclusion of BLInCs, and one in the background. (c) Image formed by subtracting an ultrasound image frame before particle activation from an image frame after 
particle activation. (d) Differential ultrasound signal as a function of time for the two featured pixels. (e) Image formed by processing to enhance the BLInCs and 
suppress the background. (f) Autocorrelation of the differential ultrasound signal for the two pixels. (g) Background-free map of the BLInCs (green) overlaid onto the 
ultrasound image of the phantom. Scale bar = 1 mm.  
 
Figure 7. (a) Three-dimensional rendering of a series of B-mode ultrasound images of a phantom. (b) Three-dimensional rendering of the BLInCs signal after 
processing the ultrasound image data to distinguish BLInCs from the background. Scale bar = 2 mm. 
 
A 3-dimensional map of the BLInCs was 
obtained by collecting and processing image data 
along several elevational planes. Figure 7a is an 
ultrasound 3D rendering of the phantom with the 
cylindrical inclusion of BLInCs. While some 
boundaries can be identified, the overall structure of 
the inclusion is difficult to discern. By applying the 
background-free imaging technique, the location of 
BLInCs was identified more clearly while suppressing 
the background signal of optical absorbers and 
acoustic scatterers (Fig. 7b). Identifying BLInCs in a 
biological environment with high sensitivity and 
contrast using could enable early detection of various 
disease markers. 
In many types of cancer, identifying the sentinel 
lymph node (SLN) is critical for accurate staging, 
because it is the first lymph node to which 
metastasized cells drain from a tumor. A mouse 
model of lymphatic drainage demonstrates the utility 
of BLInCs in SLN mapping.(32) Although ultrasound 
imaging is routinely used for lymph node imaging, 
the SLN cannot be accurately identified from anatomy 
alone. Therefore, contrast agents are helpful in 
mapping the SLN. As in the phantom imaging, laser 
pulses were used to repeatedly activate the BLInCs. 
However, the changes in echogenicity were difficult 
to detect in real time (Fig. 8a-b) due to the low 
concentration of bubbles, the highly scattering 
background, the rapid recondensation of the BLInCs 
into their liquid state, and the dB scale of ultrasound 
images. The lymph node was roughly identified using 
anatomical reference from the conventional B-mode 
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images (Fig. 8b). Using the time-series data, the rapid, 
periodic changes in echogenicity distinguished the 
BLInCs from the background by processing the 
temporal characteristics of individual image pixels. 
This resulted in a background-free map of the BLInCs, 
which was overlaid onto an ultrasound image to 
visualize them in an anatomical reference (Fig. 8c). 
Here the BLInCs are seen throughout the volume of 
the lymph node, indicating rapid drainage via the 
lymphatic system, behavior that has been previously 
observed and reported for similarly sized 
particles.(36) Blinking signal was not observed in mice 
where there was no injection of BLInCs 
(Supplementary Fig. S6). The stability of 
perfluorohexane droplets in vitro (37) and 
perfluoropentane droplets in vivo (20) suggest that 
BLInCs can circulate through the vasculature for 
several hours. Prolonged imaging may be conducted 
due to the sensitivity of the imaging procedure and 
the ability of the BLInCs to undergo repeatable 
activation, which would allow sufficient time for their 
accumulation into extravascular tissues and/or 
attachment to molecular targets. Significant blinking 
signal appears at the surface of the skin. This is most 
likely due to bubbles at the skin/gel interface, which 
oscillate in the presence of photoacoustic signal 
generation following laser irradiation. This oscillation 
appears as blinking signal, so surface bubbles should 
be minimized during this imaging process. 
Discussion 
The BLInCs facilitate a new imaging technique 
for background-free images of injected particles. 
However, the activation laser energy must be 
appropriate to allow for transient droplet 
vaporization, accounting for optical absorption and 
scattering in biological tissues. The laser fluence 
required for vaporization in a non-scattering phantom 
(Fig. 4, 5) was lower than that in a phantom 
containing optical absorbers (Fig. 6, 7) or in a mouse 
lymph node (Fig. 8). Given the optical wavelength of 
activation and sensitivity of BLInCs to vaporization, it 
is feasible that they may be imaged at depths of > 2 
cm. (38) 
To achieve both particle stability over time as 
well as high contrast from their unique blinking 
behavior, it is important activate BLInCs with a laser 
fluence that achieves repeatable, reversible phase 
changes. This is most easily accomplished by imaging 
initially at low laser fluence, and then increasing the 
energy until the blinking behavior can be observed. 
Implementing a real-time imaging algorithm would 
aid in selecting appropriate laser fluence. 
The irreversible vaporization of BLInCs (Fig. 4d) 
is possibly due to vaporization of larger BLInCs, 
coalescence of neighboring bubbles into larger stable 
bubbles, or diffusion of air into the cavity created by 
the bubble. Larger bubbles are less prone to 
recondense back into their liquid droplet form than 
very small bubbles.(27) However, smaller BLInCs 
require more laser energy to vaporize.(39–41) It is 
desirable to synthesize a monodisperse sample of 
droplets so that precise control over laser energy can 
maximize the vaporization efficiency and prevent 
irreversible vaporization. Stable bubble formation is 
ineffective for producing a background-free image, 
and the acoustic scattering from bubbles may mask 
any blinking behavior from smaller BLInCs. 
  
Figure 8. Ultrasound images of mouse tissue (a) before and (b) after optical irradiation, with a rough outline of the lymph node location. (c) The BLInCs signal, 
overlaid onto the ultrasound image, shows the location of the particles, which have accumulated in the node of the lymphatic system. Scale bar = 1 mm. 
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To construct a background-free image, the 
ultrasound image data was collected at a frame rate 
high enough to capture the rapid two-stage phase 
change of the BLInCs. The speed of the phase change 
(most notably recondensation) depends on several 
factors, including the size of the BLInCs and the 
likelihood of neighboring bubble coalescence 
following vaporization.(27) The likelihood of 
coalescence depends on the concentration of bubbles 
formed (either from a high concentration of BLInCs or 
from efficient vaporization by high laser fluence). 
Other factors may also affect speed of condensation, 
such as the stiffness of the surrounding medium and 
the ultrasound pressure field. It may be possible to 
characterize tissue properties by observing the 
dynamic behavior of the BLInCs in response to laser 
activation.  
While more than ten laser pulses were used to 
form each of the images, this technique may be carried 
out using fewer laser pulses. If the autocorrelation or a 
similar approach is used to identify blinking pixels, at 
least two laser pulses are required, although greater 
image contrast will result when more phase changes 
are measured. The laser pulse repetition frequency 
determines the imaging frame rate, thus higher frame 
rate can be achieved by using lasers with much faster 
pulse repetition frequency.  
Most pixel data of BLInCs exhibited an increase 
in echogenicity followed by a decrease in echogenicity 
at intervals corresponding to laser pulses. However, 
some pixels underwent a decrease in echogenicity 
followed by an increase, the opposite of what was 
expected. These data are possibly indicative of 
bubbles that moved while other BLInCs were being 
activated, or to surrounding pressure increases which 
induced bubble recondensation. To overcome this 
limitation, the absolute value of the difference image 
was used during formation of the background-free 
image. 
Droplet vaporization has also been triggered 
with high intensity focused ultrasound (HIFU), 
(17,42) which could also be used to trigger BLInCs 
without a laser or optical absorber. However, due to 
the high boiling point of perfluorohexane, 
vaporization with HIFU may require intensity levels 
of up to 1,000 W/cm2,(43) which is 500 times the safe 
recognized level for peripheral tissue,(44) 
compromising the safety of the imaging technique. 
Some research exists showing that the vaporization 
threshold of perfluorocarbon droplets can be reduced 
by incorporating nucleation seeds,(45,46) which may 
enable deeper, more sensitive activation of BLInCs. 
The transient phase-change behavior of BLInCs 
makes them a valuable tool for high contrast 
biomedical imaging. Any injectable particles, 
however, must be made of materials approved for 
human use before clinical translation. While the 
BLInCs reported here encapsulate a near-infrared dye 
for improved optical penetration in tissue at 1064 
nm,(47) similar particles have been made using 
clinically approved indocyanine green dye.(13) Thus 
it is feasible to synthesize BLInCs out of entirely 
approved materials to be used in a clinical setting. 
BLInCs may be used as a therapeutic tool in 
addition to their high contrast imaging utility. 
Localized drug delivery could be achieved with these 
or similar triggerable nanodroplets, whereby drug is 
released upon activation of the particle and delivery 
to the site of interest is improved through nanodroplet 
extravasation, or intracellular droplet or drug uptake 
through sonoporation.(48,49) It is possible that the 
repeatable vaporization may provide sustained 
therapeutic benefit similar to the effects of 
microbubble-assisted HIFU therapy, which is 
unattainable through irreversible optical droplet 
vaporization alone. Additionally, imaging the BLInCs 
could identify the site of therapeutic payload. 
Conclusion 
The BLInCs introduced here facilitate a new 
technique for background-free imaging of 
nanoparticles using a conventional ultrasound 
imaging system. Due to their stability and small size, 
the droplets are capable of extended circulation time 
and extravasation, a key component of imaging on the 
molecular scale. The BLInCs are made to activate 
through a unique, laser-induced rapid sequence of 
two phase changes—vaporization and 
recondensation—which is processed into a 
background-free map of the particles. This imaging 
technique is highly sensitive to diluted particles. Due 
to their blinking behavior, individual BLInCs can be 
located among the vast acoustic scatterers present in 
tissue. These experiments identify BLInCs with high 
specificity and sensitivity in the optically absorbing 
and acoustically scattering background of a living 
mouse. Furthermore, cell-specific targeting has been 
achieved with similar perfluorocarbon microbubbles 
by conjugating various molecules to the particle 
shell.(50–53) The smaller size and enhanced 
circulation time of nanodroplets make them a feasible 
candidate for molecular imaging, expanding the 
performance of this nanoparticle-based ultrasound 
imaging platform. 
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